Table 1 Patients’ clinical characteristics before and after PSM
Parameter | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
LCA preservation (n = 61) | LCA nonpreservation (n = 155) | P value | LCA preservation (n = 60) | LCA nonpreservation (n = 60) | P value | |
Age | 59.5 ± 11.3 | 59.0 ± 11.0 | 0.784 | 59.5 ± 11.4 | 60.3 ± 10.5 | 0.696 |
Sex | 0.334 | 0.855 | ||||
Male | 31 (50.8) | 90 (58.1) | 31 (51.7) | 30 (50.0) | ||
Female | 30 (49.2) | 65 (41.9) | 29 (48.3) | 30 (50.0) | ||
BMI (kg/m2) | 23.1 ± 3.3 | 23.1 ± 2.8 | 0.841 | 23.1 ± 3.3 | 23.2 ± 2.8 | 0.846 |
ASA classification | 0.190 | |||||
I | 26 (42.6) | 81 (52.2) | 26 (43.3) | 26 (43.3) | 0.843 | |
II | 28 (45.9) | 61 (39.4) | 27 (45.0) | 29 (48.3) | ||
III | 7 (11.5) | 13 (8.4) | 7 (11.7) | 5 (8.4) | ||
Tumor location | 0.719 | 0.752 | ||||
Lower (≤ 5 cm) | 16 (26.2) | 54 (34.8) | 16 (26.7) | 14 (23.3) | ||
Middle (5.1–10 cm) | 37 (60.7) | 71 (45.8) | 36 (60.0) | 38 (63.4) | ||
Upper (10.1–15 cm) | 8 (13.1) | 30 (19.4) | 8 (13.3) | 8 (13.3) | ||
Pathological stage | 0.643 | 0.866 | ||||
Stage 0 | 4 (6.5) | 9 (5.8) | 4 (6.7) | 5 (8.3) | ||
Stage 1 | 18 (29.5) | 39 (25.2) | 18 (30.0) | 14 (23.3) | ||
Stage 2 | 17 (27.9) | 45 (29.0) | 17 (28.3) | 20 (33.3) | ||
Stage 3 | 15 (24.6) | 50 (32.3) | 15 (25.0) | 16 (26.7) | ||
Stage 4 | 7 (11.5) | 12 (7.7) | 6 (10.0) | 5 (8.4) | ||
Neoadjuvant therapy | 12 (19.7) | 34 (21.9) | 0.715 | 12 (20.0) | 15 (25.0) | 0.512 |
TaTME | 0.019a | 0.817 | ||||
Yes | 11 (18.0) | 53 (34.2) | 11 (18.3) | 12 (20.0) | ||
No | 50 (82.0) | 102 (65.8) | 49 (81.7) | 48 (80.0) | ||
Ileostomy | 0.252 | 1.000 | ||||
Yes | 33 (54.1) | 97 (62.6) | 33 (55.0) | 33 (55.0) | ||
No | 28 (45.9) | 58 (37.4) | 27 (45.0) | 27 (45.0) | ||
Surgical approach | 0.058 | 0.702 | ||||
Laparoscope | 40 (65.6) | 121 (78.1) | 40 (66.7) | 38 (63.3) | ||
Robotic | 21 (34.4) | 34 (21.9) | 20 (33.3) | 22 (36.7) | ||